NCT04426669 — Intima Bioscience cancer immunotherapy trial
A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering
Registry record
| Registry ID | NCT04426669 ↗ |
|---|---|
| Lead sponsor | Intima Bioscience, Inc. |
| Collaborators | Masonic Cancer Center, University of Minnesota |
| Phase | Phase 1/2 |
| Status | Completed |
| Indication | Gastrointestinal Epithelial Cancer, Gastrointestinal Neoplasms, Cancer of Gastrointestinal Tract, Cancer, Gastrointestinal, Gastrointestinal Cancer, Colo-rectal Cancer, Pancreatic Cancer, Gall Bladder Cancer, Colon Cancer, Esophageal Cancer, Stomach Cancer |
| Enrollment | 23 participants |
| Start date | 2020-05-15 |
| Primary completion | 2025-05-28 |
| Last registry update | 23 Feb 2026 |
Every field above is mirrored from the study record on ClinicalTrials.gov (NCT04426669), which the sponsor maintains and which carries the full protocol summary, eligibility criteria, sites and contacts. No neoantigen vaccine is approved anywhere yet — every program here is investigational, and inclusion is not an endorsement. See the methodology for how the tracker is built.
Where this fits
Daily coverage of the modality, tumor type and players this study touches:
Related trials
FAQ
What phase is NCT04426669?
NCT04426669 (A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering) is registered on ClinicalTrials.gov as Phase 1/2, sponsored by Intima Bioscience, Inc..
Is NCT04426669 recruiting?
As of the 2026-02-23 registry update, NCT04426669 is listed as "Completed". Eligibility criteria, study sites and contacts are maintained by the sponsor on the ClinicalTrials.gov record.
Who is running NCT04426669?
The lead sponsor is Intima Bioscience, Inc.. Collaborators: Masonic Cancer Center, University of Minnesota.
What condition does NCT04426669 study?
The registered conditions are Gastrointestinal Epithelial Cancer, Gastrointestinal Neoplasms, Cancer of Gastrointestinal Tract, Cancer, Gastrointestinal, Gastrointestinal Cancer, Colo-rectal Cancer, Pancreatic Cancer, Gall Bladder Cancer, Colon Cancer, Esophageal Cancer, Stomach Cancer. Primary completion is listed as 2025-05-28.
Are results available for NCT04426669?
neoag.ai mirrors the registry's factual fields — sponsor, phase, status and dates — and does not publish trial results. Any posted results, publications, or outcome measures appear on the ClinicalTrials.gov record for NCT04426669.
Back to the full neoantigen vaccine trial tracker — 107 studies, refreshed daily from ClinicalTrials.gov. Background: primer, glossary, and the companies landscape.